Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature

doi:10.3748/wjg.124393

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 2

This Article

(2)

(3)

(0)

(102)

Peer-Review Report of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 14, 2027; 33(2): 124393
Published online Jan 14, 2027. doi: 10.3748/wjg.124393

Full Size Figure Download Figure

Figure 5 Timeline flowchart of patient’s diagnosis and treatment. A: Diagnostic and radiological milestones; B: Twelve treatment cycles (from March 26 to November 28, 2025): Bevacizumab 400 mg followed 1 day later by tislelizumab 200 mg, every 3 weeks. CT: Computed tomography; MSI-H: Microsatellite instability-high; TMB: Tumor mutational burden.

Citation: Chen YF, Huang C, Chen ZJ, Wang ZH. Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World J Gastroenterol 2027; 33(2): 124393
URL: https://www.wjgnet.com/1007-9327/full/v33/i2/124393.htm
DOI: https://dx.doi.org/10.3748/wjg.124393

Chen YF, Huang C, Chen ZJ, Wang ZH. Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World J Gastroenterol 2027; 33(2): 124393 [DOI: 10.3748/wjg.124393]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.